Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on February 6, 2008
Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007060712
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2007060712v1
19/5/992    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jørgensen, L.
Right arrow Articles by Jacobsen, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jørgensen, L.
Right arrow Articles by Jacobsen, B. K.
Related Collections
Right arrowRelated Article

Received June 27, 2007
Accepted on November 6, 2007

CLINICAL EPIDEMIOLOGY

Association of Albuminuria and Cancer Incidence

Lone Jørgensen *1, Ivar Heuch {dagger}, Trond Jenssen {ddagger}{sect}, and Bjarne K. Jacobsen *

*Institute of Community Medicine and {sect}Institute of Clinical Medicine, University of Tromsø, Tromsø, {dagger}Department of Mathematics, University of Bergen, Bergen, and {ddagger}Medical Department, Division of Nephrology, Rikshospitalet, Oslo, Norway


1 To whom correspondence should be addressed. E-mail: lone.jorgensen{at}ism.uit.no.


   Abstract

Albuminuria, which is associated with noncardiovascular mortality, might be a result of altered vascular permeability caused by cytokines and other tumor cell products. The aim of this population-based, longitudinal study was to examine whether elevated albumin-to-creatinine ratio (ACR) is associated with cancer incidence. A total of 5425 participants without diabetes or previous cancer in the Tromsø Study were followed; 590 had a first diagnosis of cancer during 10.3 yr of follow-up. The ACR at baseline significantly correlated with the incidence of cancer, even after adjustment for age, gender, body mass index, physical activity, and smoking (P < 0.001). Participants with ACR in the highest quintile were 8.3- and 2.4-fold more likely to receive a diagnosis of bladder cancer and lung cancer, respectively, compared with those with ACR in the lowest quintile after similar adjustments. It is concluded that albuminuria is associated with cancer incidence in individuals without a history of diabetes, macroalbuminuria, or previous cancer and that it might confer risks of varying magnitude for different types of cancer.


Related Article

This Month's Highlights
J. Am. Soc. Nephrol. 2008 19: A7. [Full Text] [PDF]






HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP